UBS analyst Joshua Spector lowered the firm’s price target on Cabot (CBT) to $74 from $75 and keeps a Neutral rating on the shares. UBS is not modeling a major change in the macro in 2026, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBT:
- Cabot price target raised to $81 from $79 at Jefferies
- Cabot signs multi-year supply agreement with PowerCo SE
- Cabot price target raised to $80 from $72 at Mizuho
- Cabot price target lowered to $54 from $75 at JPMorgan
- Cabot Corp’s AI Challenges: Navigating Risks and Competitive Pressures